Biologics License Application

Securities class action filed against uniQure alleging FDA approval misrepresentations. April 13, 2026 deadline for lead plaintiff claims.

Levi & Korsinsky sued $QURE over false FDA statements. Investors who lost money Sept-Oct 2025 can claim damages by April 13, 2026.

uniQure faces securities lawsuit for allegedly misrepresenting Huntington's study design approval and downplaying BLA delays. Investors must act by April 13, 2026.

FDA approves J&J's Tecvayli plus Darzalex Faspro for multiple myeloma with 83.3% three-year survival rate, expanding drug's label.

uniQure faces shareholder lawsuit alleging false statements on FDA approval and study design. Lead plaintiff deadline: April 13, 2026.

uniQure faces securities class action lawsuit alleging misstatements about Pivotal Study design and FDA approval. Lead plaintiff deadline: April 13, 2026.

uniQure stock plunges 49% after FDA rejects gene therapy data for AMT-130, triggering securities fraud class action lawsuit for investors trading September-October 2025.

Levi & Korsinsky files class action against Inovio Pharmaceuticals alleging management misrepresented FDA accelerated approval eligibility for lead candidate, causing stock decline.

uniQure faces securities class action over alleged misrepresentations regarding FDA approval status of Huntington's Disease trial design and regulatory timeline delays. Lead plaintiff deadline April 13, 2026.

UniQure faces securities lawsuit alleging material misrepresentations about its Huntington's Disease trial design and FDA approval status. Lead plaintiff deadline is April 13, 2026.

Law firm investigates Alvotech after FDA rejected applications following failed facility inspection, causing stock to plunge 34%. Investors sought for potential securities litigation.

uniQure faces securities class action over allegedly misleading FDA approval claims and timeline delays. Investors must act before April 13, 2026 deadline.

FDA accepts Moderna's flu vaccine application after prior rejection, setting August priority review date. Stock surges 5.77% as company expands mRNA pipeline beyond COVID-19.

UniQure faces class action lawsuit over alleged FDA disclosure misrepresentations. Investors have until April 13, 2026 deadline to join litigation.

Rosen Law Firm sued uniQure for allegedly misleading investors about FDA approval timelines and regulatory study status between September-October 2025.